Incyte (INCY) announced new data from a phase I study on pipeline candidate INCB123667 in patients with advanced solid tumors.INCB123667 is a highly selective, potential first-in-class CDK2 inhibitor.The new data was presented during a mini-oral presentation at the European Society of Medical Oncology.The updated data highlight the potential of the candidate as a differentiated treatment option for cancers with increased cyclin E1 activity, amplification and/or overexpression in cells predictive of CDK2 dep ...